These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11464277)

  • 1. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme.
    Struss AK; Romeike BF; Munnia A; Nastainczyk W; Steudel WI; König J; Ohgaki H; Feiden W; Fischer U; Meese E
    Oncogene; 2001 Jul; 20(31):4107-14. PubMed ID: 11464277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival.
    Pallasch CP; Struss AK; Munnia A; König J; Steudel WI; Fischer U; Meese E
    Int J Cancer; 2005 Nov; 117(3):456-9. PubMed ID: 15906353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
    Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
    Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
    Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHF3 expression is frequently reduced in glioma.
    Fischer U; Struss AK; Hemmer D; Michel A; Henn W; Steudel WI; Meese E
    Cytogenet Cell Genet; 2001; 94(3-4):131-6. PubMed ID: 11856869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
    Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
    Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.
    Reddy SP; Britto R; Vinnakota K; Aparna H; Sreepathi HK; Thota B; Kumari A; Shilpa BM; Vrinda M; Umesh S; Samuel C; Shetty M; Tandon A; Pandey P; Hegde S; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Kondaiah P; Somasundaram K; Rao MR
    Clin Cancer Res; 2008 May; 14(10):2978-87. PubMed ID: 18483363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
    Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS
    Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
    Wheeler CJ; Das A; Liu G; Yu JS; Black KL
    Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
    Ruano Y; Mollejo M; Camacho FI; Rodríguez de Lope A; Fiaño C; Ribalta T; Martínez P; Hernández-Moneo JL; Meléndez B
    Cancer; 2008 Apr; 112(7):1575-84. PubMed ID: 18260157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.
    Mock A; Warta R; Geisenberger C; Bischoff R; Schulte A; Lamszus K; Stadler V; Felgenhauer T; Schichor C; Schwartz C; Matschke J; Jungk C; Ahmadi R; Sahm F; Capper D; Glass R; Tonn JC; Westphal M; von Deimling A; Unterberg A; Bermejo JL; Herold-Mende C
    Oncotarget; 2015 May; 6(15):13579-90. PubMed ID: 25944688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
    Wykosky J; Gibo DM; Stanton C; Debinski W
    Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
    Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors.
    Faury D; Nantel A; Dunn SE; Guiot MC; Haque T; Hauser P; Garami M; Bognár L; Hanzély Z; Liberski PP; Lopez-Aguilar E; Valera ET; Tone LG; Carret AS; Del Maestro RF; Gleave M; Montes JL; Pietsch T; Albrecht S; Jabado N
    J Clin Oncol; 2007 Apr; 25(10):1196-208. PubMed ID: 17401009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
    Wang LF; Fokas E; Bieker M; Rose F; Rexin P; Zhu Y; Pagenstecher A; Engenhart-Cabillic R; An HX
    Oncol Rep; 2008 Jan; 19(1):151-6. PubMed ID: 18097589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum GFAP is a diagnostic marker for glioblastoma multiforme.
    Jung CS; Foerch C; Schänzer A; Heck A; Plate KH; Seifert V; Steinmetz H; Raabe A; Sitzer M
    Brain; 2007 Dec; 130(Pt 12):3336-41. PubMed ID: 17998256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.
    Quan AL; Barnett GH; Lee SY; Vogelbaum MA; Toms SA; Staugaitis SM; Prayson RA; Peereboom DM; Stevens GH; Cohen BH; Suh JH
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):695-703. PubMed ID: 15936158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue.
    Lama G; Mangiola A; Anile C; Sabatino G; De Bonis P; Lauriola L; Giannitelli C; La Torre G; Jhanwar-Uniyal M; Sica G; Maira G
    Int J Oncol; 2007 Jun; 30(6):1333-42. PubMed ID: 17487353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.